Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 11, 2026 08:01 ET | Source: Paratus Sciences Corporation

Paratus Sciences Presents Preclinical and Translational Data on PS-1001, a First-in-Class Pan-Inflammasome Inhibitor, at FOCIS 2026

PS-1001 is a potent, long-acting inflammasome inhibitor. New data support its therapeutic promise for a wide range of chronic inflammatory diseases.
June 11, 2026 08:00 ET | Source: Theriva Biologics, Inc.

Theriva™ Biologics Announces Results from VCN-01 Phase 1 Clinical Trial in Head and Neck Cancer Published in Clinical Cancer Research

– Prolonged overall survival (OS) was observed in heavily pre-treated refractory Head & Neck Squamous Cell Carcinoma (HNSCC) patients administered IV VCN-01 prior to the immune checkpoint...
June 11, 2026 07:00 ET | Source: Purple Biotech Ltd.

Purple Biotech Presents New Preclinical Data at EACR 2026 Highlighting IM1240's Anti-Tumor Activity, Favorable Safety and Pharmacokinetic Profile, and Broad Therapeutic Window

Non-human primate (NHP) toxicology study validates the CAPTN-3 masking strategy, with IM1240 showing an 8-fold longer half-life, 16-fold greater exposure, and a markedly improved cytokine-release...
June 11, 2026 07:00 ET | Source: Medicenna Therapeutics Corp.

Medicenna Strengthens U.S. Patent Estate with Newly Issued and Allowed Patents Across its IL-2, IL-4 and IL-13 Superkine Platforms

TORONTO, June 11, 2026 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company developing Superkines for...
June 11, 2026 07:00 ET | Source: AC Immune SA

AC Immune to Receive Research Grant from Goradia Family for Development of ACI-7104 in Parkinson’s Disease

AC Immune to Receive Research Grant from Goradia Family for Development of ACI-7104 in Parkinson’s Disease Grant supports extension of Part 1 of Phase 2 VacSYn trial of ACI-7104Planned extension of...
June 11, 2026 03:30 ET | Source: Scenic Biotech

Scenic Biotech Joins Michael J. Fox Foundation’s LITE Program to Explore New Disease-Modifying Approach for Parkinson's Disease

Scenic Biotech Joins Michael J. Fox Foundation’s LITE Program to Explore New Disease-Modifying Approach for Parkinson's Disease
June 11, 2026 01:00 ET | Source: F. Hoffmann-La Roche Ltd

FDA grants Priority Review for Roche’s Tecentriq for a certain type of stage III colon cancer

Filing acceptance is based on the phase III Alliance ATOMIC study showing Tecentriq plus chemotherapy reduced recurrence or death risk by 50% versus chemotherapy alone1Nearly one in three patients...
June 10, 2026 18:55 ET | Source: TermPlus

TermPlus Fixed-Term Accounts Deliver Monthly Income for some of Australia's 4.4 Million Retirees and 663,867 SMSFs - June 2026 Five-Year Target Rate 8.50%* Per Annum

Sydney, Australia, June 10, 2026 (GLOBE NEWSWIRE) -- Australians planning for retirement income face two converging trends. Around 4.4 million Australians are now aged 65 and over, about 17% of the...
June 10, 2026 09:15 ET | Source: MAIA Biotechnology, Inc.

MAIA Biotechnology Activates and Opens Enrollment at Second U.S. Clinical Site for International Phase 2 THIO-101 Expansion Trial

Additional data from MAIA’s THIO-101 expansion may further support an accelerated approval filing with the FDA Potential breakthrough therapy holds substantial commercial opportunity in a projected...
June 10, 2026 06:00 ET | Source: NorthWest Copper Corp.

NorthWest Reports Palladium Assay Results at Kwanika, Highlighting Potential for a By-Product Credit

TORONTO, June 10, 2026 (GLOBE NEWSWIRE) -- NorthWest Copper Corp. (“NorthWest” or the “Company”) (TSX-V: NWST) reports palladium assay results from stored sample pulps collected from historical...